This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe
Home   Membership   Events   Resources   Accreditation July 14, 2010
ACRO 2011 Proposed Rules webinar July 30 — free for current members
ACRO    Share   Share on FacebookTwitterShare on LinkedinE-mail article
ACRO's next free members-only reimbursement webinar by Revenue Cycle Inc. is rapidly approaching. This webinar, 2011 Proposed Rules-Medicare Physician Fee Schedule, will be at 1 p.m. EDT July 30. Click here to register today.

CDC: Colon cancer screening rates rise while those for breast cancer plateau
The Associated Press    Share    Share on FacebookTwitterShare on LinkedinE-mail article
More older Americans are getting tested for colon cancer, with nearly two out of three getting recommended screenings. Meanwhile, rates for breast cancer screening remain stuck on a higher plateau, according to a government report. U.S. health officials estimate that at least 10,000 lives could be saved each year if more people got checked. "We have further to go," said Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention. More

Study: Stress helps fend off cancer in mice
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Some stress can be good for the body, helping fight off cancer, researchers reported. Experiments with mice showed that animals put into a stressful situation, even fighting with other mice, did a better job of fighting tumors than mice left to chill out. They said their findings, published in the journal Cell, point to a possible neurological treatment for cancer. "The way we live, and how we live, may well have a much bigger impact on the prognosis of cancer than we recognized previously," Dr. Matthew During, a professor of neuroscience who worked on the study, said in a telephone interview. More

Platinum Medical Imaging: Excellence in Systems, Service, Parts, and Support

Platinum Medical Imaging specializes in working with Cancer Centers to provide factory certified, fully refurbished CT Scanners dedicated for Oncology. Visit us at

Cancer therapy goes viral: Progress is made tackling tumors with viruses
Scientific American    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The adapted virus that immunized hundreds of millions of people against smallpox now has been enlisted in the war on cancer. Vaccinia poxvirus joins a herpes virus and a host of other pathogens on a growing list of engineered viruses entering late-stage human testing against cancer. After a decade of development of so-called oncolytic viruses, the newest strains hold the most promise yet, researchers say. More

Report: US cancer death rates continue drop
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
U.S. cancer death rates are falling, with big decreases in major killers such as colon and lung cancer, the American Cancer Society said. The improvement was attributed to a decline in smoking, better treatment and earlier detection, it said. The group predicted 1,529,560 new cancer cases in the United States in 2010 and 569,490 deaths. Death rates for all cancer types fell by 2 percent a year from 2001 to 2006 among men and 1.5 percent per year from 2002 to 2006 in women, it said. More

Leeds team develops cancer drug delivery technique
The Engineer    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Leeds University researchers are developing a method for delivering chemotherapy drugs directly to the site of a tumor. The technique involves using ultrasound to burst bubbles that contain drugs. If successful, the technique could be adapted for other diseases. The project brings together engineers, physicists, chemists and cancer specialists from across the university to work on the new technique. More

Prostate cancer patients face yearlong rationing of Provenge
Bloomberg    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Prostate cancer patients seeking Dendreon Corp.'s new tumor-fighting vaccine, Provenge, face delays of a year or more as hospital waiting lists dwarf the company's capacity to produce medicine. Dendreon can only produce enough Provenge to treat about 2 percent of eligible patients until manufacturing increases in mid-2011, said Chief Operating Officer Hans Bishop. The University of Texas MD Anderson Cancer Center and Duke University's Comprehensive Cancer Center are among hospitals scrambling to decide who should get the drug. More

Go Beyond Billing

RadMax Radiation Oncology Billing Service combines advanced technology, total value, and dedicated customer service to meet all your AR management needs.

Bayer agrees to develop cancer medicines with OncoMed
Bloomberg Businessweek    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Bayer AG agreed to work with OncoMed Pharmaceuticals Inc. to develop cancer drugs that fight a group of cells that drive tumor growth and resist chemotherapy. Bayer, based in Leverkusen, Germany, will pay $40 million to OncoMed and in return get the option to buy the rights to as many as five drug candidates at any point up to the completion of the first phase of clinical trials, according to a statement from the companies. More

Novartis's Afinitor keeps NET cancer at bay longer
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Novartis AG's cancer drug Afinitor more than doubles the time patients with a certain type of pancreatic cancer live without tumor growth, the Swiss drugmaker said on July 1. Novartis already has said it plans worldwide regulatory filings this year for the potential billion-dollar seller after the drug met its primary goal in a Phase III study by significantly extending progression-free survival in patients with advanced pancreatic neuroendocrine tumors. More

Radiation Oncology Consulting

Churchill Consulting, Inc., providing expert products and services since 1992. Premier product is DIRECTREES® (coding help application). Services include comprehensive chart audits, coding seminars, compliance programs, and QA Programs

Roche files BLA for breakthrough T-DM1 cancer therapy
FierceBiotech    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Wowed by stellar mid-stage data, Roche has filed a BLA for trastuzumab-DM1, or T-DM1, seeking approval to market the pioneering conjugated monoclonal antibody to women with treatment-resistant HER2 positive breast cancer. For Roche, T-DM1 represents a potential mega-blockbuster capable of eventually rivaling Herceptin in the market for cancer drugs. And the filing marks a major milestone for the investigators at Genentech and Immunogen who successfully combined a monoclonal antibody with a toxic chemotherapy to single out cancer cells for termination, sparing healthy cells. More

UK health body rejects Herceptin for gastric cancer
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail
Britain's health cost watchdog has rejected Roche's cancer drug Herceptin for patients with stomach cancer, which means they will not get the drug paid for by the country's taxpayer-funded National Health Service. The National Institute for Health and Clinical Excellence said it was rejecting the drug, whose generic name is trastuzumab, for gastric cancer "due to the uncertainty surrounding the extent to which it can extend life." Herceptin works only in cancer patients whose tumors have high levels of human epidermal growth factor receptor 2 and is not suitable for others. More

Why skin cancer is on the rise
Live Science    Share    Share on FacebookTwitterShare on LinkedinE-mail article
For years, millions of sun worshippers across the country have hit the beaches during summer to work on the perfect, golden tan. However, the advent of indoor tanning salons now allows Americans to sport a sun-kissed look year-round. And as more and more people pursue a perpetual summer-style tan, dermatologists have begun to notice a significant rise in skin cancer incidents, especially among young women. More


See 6 inspiring user presentations from the TomoTherapy 2010 User Education Symposia. More

RadOnc Weekly
James DeBois, Director of Advertising Sales, 469.420.2618   Download media kit
Patrick McCoy, Content Editor, 469.420.2603   Contribute news
This edition of RadOnc Weekly was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
July 7, 2010
June 30, 2010
June 23, 2010
June 16, 2010

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063